Cargando…

Effects of paroxetine-mediated inhibition of GRK2 expression on depression and cardiovascular function in patients with myocardial infarction

BACKGROUND: Paroxetine is a selective serotonin reuptake inhibitor utilized in the treatment of depression and anxiety disorders. Recent studies have identified paroxetine as a G protein-coupled receptor kinase-2 (GRK2) inhibitor capable of reversing cardiac dysfunction and remodeling in experimenta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Xiuqing, Wang, Qing, Guo, Rui, Xu, Lingling, Chen, Qin M, Hou, Yinglong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5028169/ https://www.ncbi.nlm.nih.gov/pubmed/27695334 http://dx.doi.org/10.2147/NDT.S109880

Ejemplares similares

Reversing T Cell Dysfunction to Boost Glioblastoma Immunotherapy by Paroxetine‐Mediated GRK2 Inhibition and Blockade of Multiple Checkpoints through Biomimetic Nanoparticles
por: Wang, Tingting, et al.
Publicado: (2023)

Paroxetine Attenuates Cardiac Hypertrophy Via Blocking GRK2 and ADRB1 Interaction in Hypertension
por: Sun, Xuejing, et al.
Publicado: (2020)

Computational study of paroxetine-like inhibitors reveals new molecular insight to inhibit GRK2 with selectivity over ROCK1
por: Keretsu, Seketoulie, et al.
Publicado: (2019)

Paroxetine protects against bleomycin-induced pulmonary fibrosis by blocking GRK2/Smad3 pathway
por: Zhao, Kaochang, et al.
Publicado: (2023)

GRK5‐mediated inflammation and fibrosis exert cardioprotective effects during the acute phase of myocardial infarction
por: Nagasaka, Akiomi, et al.
Publicado: (2023)

Antagonistic Roles of GRK2 and GRK5 in Cardiac Aldosterone Signaling Reveal GRK5-Mediated Cardioprotection via Mineralocorticoid Receptor Inhibition
por: Maning, Jennifer, et al.
Publicado: (2020)

GRK2 inhibitors, paroxetine and CCG258747, attenuate IgE-mediated anaphylaxis but activate mast cells via MRGPRX2 and MRGPRB2
por: Thapaliya, Monica, et al.
Publicado: (2022)

GRK 2 level in peripheral blood lymphocytes of elderly patients with acute myocardial infarction
por: Gao, Wen-Qian, et al.
Publicado: (2013)

Effectiveness of paroxetine in the treatment of poststroke depression
por: Ma, Chen, et al.
Publicado: (2018)

The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers
por: Iborra-Egea, Oriol, et al.
Publicado: (2022)

GRK2 Mediates Macrophage Polarization by Regulating EP4-cAMP-pCREB Signaling in Ulcerative Colitis and the Therapeutic Effect of Paroxetine on Mice with DSS-Induced Colitis
por: Zhang, Jiawei, et al.
Publicado: (2023)

Paroxetine in the treatment of recurrent brief depressive disorder
por: Prakash, Sathya, et al.
Publicado: (2013)

Paroxetine‐Mediated G‐Protein Receptor Kinase 2 Inhibition in Patients With Acute Anterior Myocardial Infarction: Final 1‐Year Outcomes of the Randomized CARE‐AMI Trial
por: Pilgrim, Thomas, et al.
Publicado: (2022)

Paroxetine overdose
por: Gupta, Arun K., et al.
Publicado: (2005)

Comparison of Tolerance of Venlafaxine, Paroxetine and Amitriptyline in Depression Therapy
por: Miskovic, Mirjana
Publicado: (2015)

Mechanism of Paroxetine (Paxil) Inhibition of the Serotonin Transporter
por: Davis, Bruce A., et al.
Publicado: (2016)

Antidepressant and Neuroprotective Effects of 3-Hydroxy Paroxetine, an Analog of Paroxetine in Rats
por: Hernández-Arrambide, Pedro Efraín, et al.
Publicado: (2022)

Paroxetine treatment in an animal model of depression improves sperm quality
por: Aghajani, Reyhane, et al.
Publicado: (2022)

Myocardial GRK2 Reduces Fatty Acid Metabolism and β-Adrenergic Receptor-Mediated Mitochondrial Responses
por: Zhai, Ruxu, et al.
Publicado: (2022)

Paroxetine-induced galactorrhea
por: Gulati, Prannay, et al.
Publicado: (2014)

Paroxetine-induced galactorrhea
por: Petrykiv, S., et al.
Publicado: (2022)

Correction: Maning et al. Antagonistic Roles of GRK2 and GRK5 in Cardiac Aldosterone Signaling Reveal GRK5-Mediated Cardioprotection via Mineralocorticoid Receptor Inhibition. Int. J. Mol. Sci. 2020, 21, 2868
por: Maning, Jennifer, et al.
Publicado: (2021)

Trafficking GRK2: Cellular and Metabolic consequences of GRK2 subcellular localization.
por: Sorriento, Daniela, et al.
Publicado: (2014)

Suitability of GRK Antibodies for Individual Detection and Quantification of GRK Isoforms in Western Blots
por: Reichel, Mona, et al.
Publicado: (2022)

Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
por: Chen, Jian-wei, et al.
Publicado: (2018)

Comparison Between Tadalafil Plus Paroxetine and Paroxetine Alone in the Treatment of Premature Ejaculation
por: Moudi, Emadouddin, et al.
Publicado: (2016)

GRK5 – A Functional Bridge Between Cardiovascular and Neurodegenerative Disorders
por: Hendrickx, Jhana O., et al.
Publicado: (2018)

Degradation of GRK2 and AKT is an early and detrimental event in myocardial ischemia/reperfusion
por: Penela, Petronila, et al.
Publicado: (2019)

Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder
por: Aldosary, Fahad, et al.
Publicado: (2021)

Specific Pharmacological Effects of Paroxetine Comprise Psychological but Not Somatic Symptoms of Depression
por: Schalet, Benjamin D., et al.
Publicado: (2016)

Paroxetine alleviates T lymphocyte activation and infiltration to joints of collagen-induced arthritis
por: Wang, Qingtong, et al.
Publicado: (2017)

GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action
por: Lee, Seunghun P., et al.
Publicado: (2021)

Quantitative Modeling of GRK-Mediated β2AR Regulation
por: Vayttaden, Sharat J., et al.
Publicado: (2010)

GRK Mediates μ-Opioid Receptor Plasma Membrane Reorganization
por: Gondin, Arisbel B., et al.
Publicado: (2019)

Paroxetine‐induced QTc prolongation
por: Otsuka, Yuji
Publicado: (2017)

Paroxetine overdose during pregnancy
por: Acar, Selin, et al.
Publicado: (2021)

The effects of paroxetine therapy on depressive symptom and motor function in the treatment of depression with Parkinson’s disease: A meta-analysis
por: Jiang, Li-Lin, et al.
Publicado: (2023)

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
por: Kamijima, Kunitoshi, et al.
Publicado: (2013)

Exposure–outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics
por: Kim, Jung-Ryul, et al.
Publicado: (2015)

White Matter Microstructure Alterations Associated With Paroxetine Treatment Response in Major Depression
por: Vieira, Rita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ici4tqvtvldcuq9vj05l3e1s6k